bleeding

6-Aminocaproic acid (EACA) is an antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.

Norethindrone (Norethisterone) is a synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for contraception.

Nitroprusside disodium dihydrate (Sodium Nitroprusside Dihydrate) is a potent vasodilator working through releasing NO spontaneously in blood.

Carbetocin is an obstetric drug used to control postpartum hemorrhage and bleeding after giving birth.

Norethynodrel (Lynestrol) is a synthetic progestational hormone with actions and uses similar to those of PROGESTERONE. It has been used in the treatment of functional uterine bleeding and endometriosis. As a contraceptive, it has usually been administered in combination with MESTRANOL.

Lanraplenib succinate inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans. Lanraplenib succinate is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases.

Lanraplenib monosuccinate inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans. Lanraplenib monosuccinate is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases.

Lanraplenib (GS-9876) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) being developed for treating inflammatory diseases. It inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.

Lysipressin ([Lys8]-Vasopressin), Induces contraction of the rabbit urinary bladder smooth muscle, activate adenylate-cyclase. Lysipressin is Antidiuretic hormone that have been found in pigs and some marsupial families.

Fibrin, the primary constituent of blood clots, is an insoluble protein essential for coagulation. Isolated from bovine blood, this protein is notably synthesized in response to bleeding.

Terlipressin Acetate, a highly selective vasopressin V1 receptor agonist, on oxygen and glucose deprivation re-oxygenation (OGD R)-induced damage in intestinal epithelial cells (IEC-6).Terlipressin acetate exerts anti-inflammatory and anti-oxidative effects. Terlipressin acetate has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock research.

Carboprost tromethamine, a synthetic 15-methyl analogue of prostaglandin F2α, effectively promotes uterine contractions and significantly reduces bleeding during and post-delivery.

Odiparcil is an orally active beta-d-thioxyloside analog. Odiparcil is an indirect thrombin inhibitor that exerts its anticoagulant effect through activation of antithrombin II (heparin cofactor II). It also has an antithrombotic activity associated with a reduced risk of adverse bleeding events.

PAR4 antagonist7 (Compound 20f) is a selective PAR4 antagonist (IC50: 1.72 nM), effective in inhibiting platelet aggregation induced by PAR4 agonists. It exhibits good metabolic stability and has not shown any tendency to cause bleeding in mice.

DSPE-PEG(2000)-azide is a PEGylated derivative based on 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (1,2-DSPE). This compound is utilized for attaching vascular cell adhesion molecule-1 (VCAM-1) antibodies to vesicles that encapsulate fingolimod, aiming to target the delivery of fingolimod to inflammatory vessels in mouse models simulating post-ischemic neuroinflammation. Additionally, DSPE-PEG(2000)-azide is employed to link fibrinogen mimetic peptides (FMP) to the surface of synthetic platelets used in treating uncontrollable bleeding caused by liver damage in mouse models.

Cyclocumarol is an anticoagulant with less potency than warfarin. Improper use of this compound may cause bleeding.

Ro 44-3888, the active component of sibrafiban, achieves predictable plasma concentrations when administered orally in its prodrug form, Ro 48-3657. Upon reaching a steady state after the second dose, Ro 44-3888 exhibits concentration-dependent inhibition of platelet aggregation and prolongs bleeding time. These findings suggest that Ro 44-3888 merits further evaluation, especially in patients at high risk of arterial thrombosis and those with acute coronary syndrome, due to its reliable absorption.

1,2,3,4,7,8-Hexachlorodibenzo-p-dioxin is a polychlorinated dibenzodioxin (PCDD) congener. At the highest dose (10,000 μg kg), it can cause hepatic pallor (fatty liver), gastrointestinal bleeding, and early mortality in H W and A strain rats. Additionally, 1,2,3,4,7,8-Hexachlorodibenzo-p-dioxin induces liver sinusoidal dilatation and can lead to severe purpura in B strain rats.

Gemeprost, an analog of prostaglandin E1, is used for the treatment of obstetric bleeding. It is used to terminate pregnancy up to 24 weeks gestation together with mifepristone.

MRS2179 is a competitive P2Y1 receptor antagonist (Kb = 100 nM) with no appreciable activity at P2Y2, P2Y4, or P2Y6 at concentrations up to 30 µM, or at P2Y12 and P2Y13. It inhibits ADP-induced platelet shape change and aggregation (pA2 = 6.55) in vitro a

Onapristone, a progesterone receptor antagonist, is used potentially for the treatment of breast cancer, advanced prostate cancer, and inducer of vaginal bleeding.

R-1663 is a factor Xa inhibitor. R-1663 prolonged clotting times, inhibited thrombin generation (peak height and endogenous thrombin potential [ETP]) and anti-factor Xa activity in a concentration-dependent manner without increasing bleeding time. Pharmac

AZD1283 is an effective P2Y12 receptor antagonist (EC50: 3.0 ug kg min, binding IC50: 11 nM). AZD1283 dose-dependently induced increases in blood flow and inhibition of ADP-induced platelet aggregation with antithrombotic ED50 values of 3.0 and 10 μg kg min, respectively. The doses induced the increase in bleeding time at 33 and 100 μg kg min for 3- and 13-fold, respectively. Thus, the therapeutic index (TI) was ≥10 for both compounds.

Aspalatone is an anti-platelet aggregator (IC50 = 180 μM, in vitro) that prolongs bleeding time significantly in a rodent model of thromboembolism. Additionally at a minimal effective dose of 24 mg/kg, aspalatone generates antioxidant and neuroprotective effects against kainic acid-induced epilepsy in rat hippocampus.